Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Bellevue Funds Lux - BB Adamant Biotech

+ Add to Watchlist

M0U2:GR

501.7200 EUR 2.2370 0.44%

As of 10:30:44 ET on 05/29/2015.

Snapshot for Bellevue Funds Lux - BB Adamant Biotech (M0U2)

Open: 502.5200 High - Low: 502.5200 - 498.3400 Primary Exchange: Frankfurt
Volume: 30 52-Week Range: 248.3200 - 530.2600 Beta vs DAX: 0.7782

ETF Chart for M0U2

No chart data available.
  • M0U2:GR 501.7200
  • 1D
  • 1M
  • 1Y
503.9570
Interactive M0U2 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for M0U2

Bellevue Funds (Lux) - BB Adamant Biotech is an open-end investment fund incorporated in Luxembourg. The Fund's objective is long-term capital appreciation. The Fund invests mainly in equities and equity related securities of companies that are directly involved in the biotechnology sector.

Inception Date: 2009-03-31 Telephone: 41-44-267-67-00
Managers: DANIEL KOLLER
Web Site: www.bellevuegroup.com

Fundamentals for M0U2

NAV -
Assets (M) (on 2015-05-28) 98.3330
Shares out (M) 0.00
Market Cap (M) 0.00
% Premium -
Average 52-Week % Premium -
Fund Leveraged N

Dividends for M0U2

No dividends reported

Performance for M0U2

1-Month +6.62% 1-Year +101.39%
3-Month +9.42% 3-Year +49.80%
Year To Date +34.16% 5-Year +34.35%
Expense Ratio -

Top Fund Holdings for M0U2

Filing Date: 04/30/2015
Name Position Value % of Total
Biogen Inc 20,000 7,478,600 7.731%
Gilead Sciences Inc 72,000 7,236,720 7.481%
Celgene Corp 63,000 6,807,780 7.038%
Amgen Inc 30,866 4,874,050 5.039%
Mylan NV 55,000 3,974,300 4.109%
Vertex Pharmaceuticals Inc 28,500 3,513,480 3.632%
Alexion Pharmaceuticals Inc 20,746 3,510,846 3.629%
Regeneron Pharmaceuticals Inc 7,595 3,474,409 3.592%
Incyte Corp 33,352 3,240,480 3.350%
Medivation Inc 24,300 2,933,982 3.033%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil